Efficacy of sofosbuvir and velpatasvir (Epclusa)

The safety and efficacy of the sofosbuvir and velpatasvir (Epclusa) combination for 12 weeks of treatment were evaluated in three Phase III clinical trials involving 1,558 subjects without cirrhosis or with compensated cirrhosis (mild cirrhosis). The results showed that 95–99% of subjects who received the combination of sofosbuvir and velpatasvir had no detectable virus in their blood 12 weeks after the end of treatment, indicating that the subjects' infection had been cured.

The safety and efficacy of the combination of sofosbuvir and velpatasvir was also evaluated in a clinical trial of 267 subjects with decompensated cirrhosis (moderate to severe cirrhosis), in which /span>87 subjects received the combination of sofosbuvir and velpatasvir combined with ribavirin for 12 weeks, and 94% of these subjects had no detectable virus in their blood 12 weeks after the end of treatment. The safety and efficacy of the combination with sofosbuvir and velpatasvir was demonstrated in adult and pediatric subjects with HCV genotype 1, 2, 3, 4 or 6 infection for the treatment of HCV genotype 5 in pediatric subjects aged 6 years and older or weighing at least 37 pounds without cirrhosis or with mild cirrhosis.

The original drug of sofosbuvir and velpatasvir has been launched in China and has entered the scope of Class B medical insurance. The domestic trade name is protonsa, and the specification is (400mg+100mg) * 28 tablets. The price per box is about RMB 4,000. The original drug of sofosbuvir and velpatasvir has also been launched overseas. There are also generic drugs of sofosbuvir and velpatasvir produced in other countries. The specifications of the Bangladesh Everest Pharmaceutical Factory are (400mg + 100mg) * 28 tablets per box, and the price is around RMB 850 (the price may fluctuate due to the exchange rate). The generic drugs produced abroad are basically the same as the original drugs at home and abroad.